SCNTP™ · for investors
SCNTP™ for Investors: the Programme, the Evidence, the Conversation
The short answer. SCNTP™ is Panacea Bio Chem's research programme on the cost of patient-matched pluripotent stem cells. The science of producing them by somatic cell nuclear transfer is published and real; the economics are not solved. This page states the problem, the evidence state and the programme's angle — honestly, with sources — and how to open a conversation. It carries no financial projections, because none are being made here.
The problem: a proven cell that costs too much
Patient-specific pluripotent stem cells — cells that match one person's genome and can become any tissue — are among the most valuable objects in regenerative medicine. Human embryonic stem-cell lines were derived by somatic cell nuclear transfer in 2013[PubMed] and from adult cells, including those of a diabetic patient, in 2014.[PubMed] The biology works at the bench.
What keeps it out of routine reach is cost, and the cost has named components: oocytes are scarce, micromanipulation is artisanal, and cloning efficiencies stay low even in the best primate work.[PubMed] A protocol that moves any of those components moves the whole economics of the field. That is the problem SCNTP™ exists to work on.
Where the evidence stands
Presented by class, because that is how this estate reports science:
Established
The nuclear reset to pluripotency is demonstrated across species — from Gurdon's 1962 frogs[PubMed] and Dolly[PubMed] to cloned macaques in 2018.[PubMed] Factor-based reprogramming (iPSC) achieves the same reset without an egg and took the 2012 Nobel Prize.[PubMed]
Human · in vitro
Patient-matched pluripotent lines by SCNT exist in the published record.[PubMed][PubMed] The nearest clinical use of pluripotent-cell therapy is iPSC-based: an autologous iPSC-derived retinal transplant was reported in 2017.[PubMed]
Open
Efficiency, oocyte supply and cost. No SCNT-derived cell therapy has regulatory approval anywhere as of September 2026. The field's improvement strategies are an active research front,[PubMed] and its governance frame — the WHO resolutions of 1997 and 1998 — rejects reproductive cloning while therapeutic research proceeds under national oversight.[WHO IRIS]
The field also carries a caution: the 2004–2005 human-SCNT claims that made headlines were retracted as fabricated in January 2006.[PubMed] Any serious position in this space starts from sources, not headlines — which is why this site cites primary literature on every claim.
The programme's angle
SCNTP™ attacks the cost problem on more than one axis at once: the protocol itself, designed from the start for cost, and the chemistry and preservation around it, engineered in-house. Panacea Bio Chem's stack — the Peptourbillon™ peptide architecture, Lyoprester® preservation, Cryolapse™ cryogenic processing and S3Pulse™ control — exists because delicate biologicals fail or succeed on exactly those axes.
The programme is a direction of work, presented as such. Its parameters are proprietary and not publicly disclosed. What is public — the science, the evidence state, the historical record — is documented on this site with primary sources: the homepage essay, the science page and the legacy page.
Who leads it
Bogdan Dicoias, biochemist and inventor, originated the SCNTP™ programme and leads it: Director of Panacea Bio Chem Ltd and Scientific Director at Biogenther, his Dominican Republic company, through which he is directly involved in this field — biogenther.com.
SCNTP™ is a proprietary Panacea Bio Chem programme developed and invented by Bogdan Dicoias. Its parameters are not publicly disclosed.
The conversation
The route to the programme is direct: write to contact@panaceabiochem.com and say what you want to discuss — the science, the programme, or a collaboration. A person reads it.
